The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry
Piero Ruscitti,Jurgen Sota,Antonio Vitale,Giuseppe Lopalco,Florenzo Iannone,Maria Morrone,Henrique Ayres Mayrink Giardini,Marília Ambuel D'Agostin,Isabelle Parente de Brito Antonelli,Ibrahim Almaghlouth,Kazi Nur Asfina,Najma Khalil,Petros P Sfikakis,Katerina Laskari,Maria Tektonidou,Francesco Ciccia,Daniela Iacono,Flavia Riccio,Gaafar Ragab,Mohamed A Hussein,Marcello Govoni,Francesca Ruffilli,Haner Direskeneli,Fatma Alibaz-Oner,Roberto Giacomelli,Luca Navarini,Elena Bartoloni,Ilenia Riccucci,Eduardo Martín-Nares,Jiram Torres-Ruiz,Paola Cipriani,Ilenia Di Cola,José Hernández-Rodríguez,Verónica Gómez-Caverzaschi,Lorenzo Dagna,Alessandro Tomelleri,Joanna Makowska,Olga Brzezinska,Annamaria Iagnocco,Elisa Bellis,Valeria Caggiano,Carla Gaggiano,Maria Tarsia,Ilaria Mormile,Giacomo Emmi,Paolo Sfriso,Sara Monti,Şükran Erten,Emanuela Del Giudice,Riccardo Lubrano,Giovanni Conti,Alma Nunzia Olivieri,Alberto Lo Gullo,Samar Tharwat,Anastasios Karamanakos,Antonio Gidaro,Maria Cristina Maggio,Francesco La Torre,Fabio Cardinale,Benson Ogunjimi,Armin Maier,Gian Domenico Sebastiani,Daniela Opris-Belinski,Micol Frassi,Ombretta Viapiana,Emanuele Bizzi,Francesco Carubbi,Lampros Fotis,Abdurrahman Tufan,Riza Can Kardas,Ewa Więsik-Szewczyk,Karina Jahnz-Różyk,Claudia Fabiani,Bruno Frediani,Alberto Balistreri,Donato Rigante,Luca Cantarini
DOI: https://doi.org/10.1016/j.semarthrit.2023.152244
Abstract:Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.